MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/acn3.51492

Медицинская библиотека · Annals of clinical and translational neurology · 2022

Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.

Cortés-Vicente Elena, Álvarez-Velasco Rodrigo, Pla-Junca Francesc, Rojas-Garcia Ricard, Paradas Carmen, Sevilla Teresa, Casasnovas Carlos, Gómez-Caravaca María Teresa, Pardo Julio, Ramos-Fransi Alba, Pelayo-Negro Ana Lara, Gutiérrez-Gutiérrez Gerardo, Turon-Sans Janina, López de Munain Adolfo, Guerrero-Sola Antonio, Jericó Ivonne, Martín María Asunción, Mendoza María Dolores, Morís Germán, Vélez-Gómez Beatriz, Garcia-Sobrino Tania, Pascual-Goñi Elba, Reyes-Leiva David, Illa Isabel, Gallardo Eduard

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

METHODS

This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients were considered refractory when their MG Foundation of America post-interventional status (MGFA-PIS) was unchanged or worse after corticosteroids and two or more other immunosuppressive agents. Clinical and immunologic characteristics of drug-refractory patients, efficiency and toxicity of drugs used, and outcome (MGFA-PIS) at end of follow-up were studied.

RESULTS

We included 990 patients from 15 hospitals. Eighty-four patients (68 of 842 anti-acetylcholine receptor [AChR], 5 of 26 anti-muscle-specific tyrosine kinase [MusK], 10 of 120 seronegative, and 1 of 2 double-seropositive patients) were drug refractory. Drug-refractory patients were more frequently women (p < 0.0001), younger at onset (p < 0.0001), and anti-MuSK positive (p = 0.037). Moreover, they more frequently presented a generalized form of the disease, bulbar symptoms, and life-threatening events (p < 0.0001; p = 0.018; and p = 0.002, respectively) than non-drug-refractory patients. Mean follow-up was 9.8 years (SD 4.5). Twenty-four (50%) refractory patients had side effects to one or more of the drugs. At the end of follow-up, 42.9% of drug-refractory patients (42.6% of anti-AChR, 100% of anti-MuSK, and 10% of seronegative patients) and 79.8% of non-drug-refractory patients (p < 0.0001) achieved remission or had minimal manifestations. Eighty percent of drug-refractory-seronegative patients did not respond to any drug tested.

INTERPRETATION: In this study, 8.5% of MG patients were drug-refractory. New more specific drugs are needed to treat drug-refractory MG patients.

Для цитирования: Cortés-Vicente Elena, Álvarez-Velasco Rodrigo, Pla-Junca Francesc, Rojas-Garcia Ricard, Paradas Carmen, Sevilla Teresa, Casasnovas Carlos, Gómez-Caravaca María Teresa, Pardo Julio, Ramos-Fransi Alba, Pelayo-Negro Ana Lara, Gutiérrez-Gutiérrez Gerardo, Turon-Sans Janina, López de Munain Adolfo, Guerrero-Sola Antonio, Jericó Ivonne, Martín María Asunción, Mendoza María Dolores, Morís Germán, Vélez-Gómez Beatriz, Garcia-Sobrino Tania, Pascual-Goñi Elba, Reyes-Leiva David, Illa Isabel, Gallardo Eduard. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.. Annals of clinical and translational neurology. 2022. DOI: 10.1002/acn3.51492.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.